当前位置:首页>产品中心>单抗/多抗>HEK293T SARS-CoV-2 Spike (PP) Stable Cell Line|HEK293T SARS-CoV-2刺突(PP)稳定细胞系(靶标:新冠病毒刺突蛋白(PP突变)稳定表达细胞系)

HEK293T SARS-CoV-2 Spike (PP) Stable Cell Line|HEK293T SARS-CoV-2刺突(PP)稳定细胞系(靶标:新冠病毒刺突蛋白(PP突变)稳定表达细胞系)

  • 货号:RB9TVK474818
  • 价格:面议
  • 点击:391

产品介绍

产品参数

宿主种属HEK293T
应用FCM
靶标SARS-CoV-2 Spike (PP)
稳定性和储存Frozen in liquid nitrogen.
登录号P0DTC2
背景信息

Spike glycoprotein (SARS-CoV-2 Spike (PP)) is a ~141 kDa protein. Attaches the virion to the cell membrane by interacting with host receptor, initiating the infection. The major receptor is host ACE2. When S2/S2' has been cleaved, binding to the receptor triggers direct fusion at the cell membrane. When S2/S2' has not been cleaved, binding to the receptor results in internalization of the virus by endocytosis using host TFRC and GRM2 and leading to fusion of the virion membrane with the host endosomal membrane. Alternatively, may use NRP1/NRP2 and integrin as entry receptors.

1. Hoffmann, M. et al. (2020) Cell 181, 271-280.e8. PMID: 32142651
2. Walls, AC. et al. (2020) Cell 181, 281-292.e6. PMID: 32155444
3. Cao, W. et al. (2021) Biophysical journal 120, 1011-1019. PMID: 33607086
4. Takeda, M. (2022) Microbiology and immunology 66, 15-23. PMID: 34561887
5. Wrapp, D. et al. (2020) Science (New York, N.Y.) 367, 1260-1263. PMID: 32075877
6. Ou, X. et al. (2020) Nature communications 11, 1620. PMID: 32221306
7. Wang, J. et al. (2021) Cell discovery 7, 119. PMID: 34903715
8. Wang, X. et al. (2023) Journal of virology 97, e0161122. PMID: 36779763
9. Daly, JL. et al. (2020) Science (New York, N.Y.) 370, 861-865. PMID: 33082294
10. Cantuti-Castelvetri, L. et al. (2020) Science (New York, N.Y.) 370, 856-860. PMID: 33082293
产品特性Growth Properties: Adherent; Selection Marker: Puromycin (1 μg/mL)
种属Viral (SARS-CoV-2)
【仅供科学研究使用】

相关产品:
产品名称 点击数
Anti-Ixekizumab Non-Neutralizing Recombinant Antibody |抗依奇珠单抗非中和重组抗体(靶标:依奇珠单抗非中和抗体) 398
Anti-Ixekizumab Non-Neutralizing Recombinant Antibody |抗依奇珠单抗非中和重组抗体(靶标:依奇珠单抗非中和抗体) 393
Anti-Ixekizumab Non-Neutralizing Recombinant Antibody |抗依奇珠单抗非中和重组抗体(靶标:依奇珠单抗非中和抗体) 582
Anti-Ixekizumab Neutralizing Recombinant Antibody |抗依奇珠单抗中和重组抗体(靶标:依奇珠单抗中和抗体) 555
Anti-Ixekizumab Neutralizing Recombinant Antibody |抗依奇珠单抗中和重组抗体(靶标:依奇珠单抗中和抗体) 496
Anti-Ixekizumab Neutralizing Recombinant Antibody |抗依奇珠单抗中和重组抗体(靶标:依奇珠单抗中和抗体) 460
Anti-Daratumumab Non-Neutralizing Recombinant Antibody|抗达雷妥尤单抗非中和重组抗体(靶标:达雷妥尤单抗非中和抗体) 527
Anti-Daratumumab Neutralizing Recombinant Antibody |抗达雷妥尤单抗中和重组抗体(靶标:达雷妥尤单抗中和抗体) 567
Anti-Daratumumab Neutralizing Recombinant Antibody |抗达雷妥尤单抗中和重组抗体(靶标:达雷妥尤单抗中和抗体) 516
Anti-Daratumumab Neutralizing Recombinant Antibody |抗达雷妥尤单抗中和重组抗体(靶标:达雷妥尤单抗中和抗体) 630
Anti-Daratumumab Neutralizing Recombinant Antibody |抗达雷妥尤单抗中和重组抗体(靶标:达雷妥尤单抗中和抗体) 601
Anti-Avelumab Non-Neutralizing Recombinant Antibody |抗阿维鲁单抗非中和重组抗体(靶标:阿维鲁单抗非中和抗体) 315
Anti-Avelumab Non-Neutralizing Recombinant Antibody |抗阿维鲁单抗非中和重组抗体(靶标:阿维鲁单抗非中和抗体) 384
Anti-Avelumab Non-Neutralizing Recombinant Antibody |抗阿维鲁单抗非中和重组抗体(靶标:阿维鲁单抗非中和抗体) 567
Anti-Avelumab Non-Neutralizing Recombinant Antibody |抗阿维鲁单抗非中和重组抗体(靶标:阿维鲁单抗非中和抗体) 394
Anti-Avelumab Neutralizing Recombinant Antibody |抗阿维鲁单抗中和重组抗体(靶标:阿维鲁单抗中和抗体) 584
Anti-Avelumab Neutralizing Recombinant Antibody |抗阿维鲁单抗中和重组抗体(靶标:阿维鲁单抗中和抗体) 390
Anti-Camrelizumab Neutralizing Recombinant Antibody |抗卡瑞利珠单抗中和重组抗体(靶标:卡瑞利珠单抗中和抗体) 633
Anti-Camrelizumab Neutralizing Recombinant Antibody |抗卡瑞利珠单抗中和重组抗体(靶标:卡瑞利珠单抗中和抗体) 611
Anti-Camrelizumab Neutralizing Recombinant Antibody |抗卡瑞利珠单抗中和重组抗体(靶标:卡瑞利珠单抗中和抗体) 546
总计 33037 个记录,共 1652 页,当前第 1648 页 | 第一页 上一页 下一页 最末页
在线客服
  • 销售热线:
  • 15898894496(同微信)
  • 我要留言
  • 周一至周五每天9:00-17:00